Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Aspirin is a cornerstone in cardiovascular disease (CVD) prevention.
• Individual variability exists in aspirin's antiplatelet efficacy.
• Residual platelet thromboxane B2 (TXB2) production indicates suboptimal aspirin response.

Purpose of the Study:

• To investigate factors influencing residual TXB2 production in patients on chronic enteric-coated aspirin.
• To evaluate the impact of concomitant medications, particularly statins, on aspirin response.
• To elucidate the mechanism by which statins affect aspirin's antiplatelet activity.

Main Methods:

• Studied 182 patients on chronic enteric-coated aspirin (100 mg/day).
• Assessed residual serum TXB2 levels, platelet aggregation, and urinary 11-dehydro-TXB2.
• Utilized in vitro experiments to examine atorvastatin's effect on platelet COX-1 acetylation.

Main Results:

• 14% of patients exhibited elevated residual serum TXB2 levels, indicating an inadequate aspirin response.
• Statin coadministration (primarily atorvastatin) was an independent predictor of lower residual TXB2.
• In vitro studies showed atorvastatin enhances aspirin acetylation of platelet COX-1.

Conclusions:

• Statin use is associated with improved aspirin efficacy in patients with CVD.
• Atorvastatin may overcome mechanisms of reduced aspirin bioavailability through enhanced COX-1 acetylation.
• Concomitant statin therapy could be beneficial for optimizing aspirin's antiplatelet effect in certain patient populations.